ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients. Marion Munk, MD, PhD, talked with Modern Retina® during the ...
Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space.
The submission was based on the safety and efficacy data from the phase 3 (RHODOS) and phase 4 (LEROS) studies. The US Food and Drug Administration (FDA) has granted Priority Review to Chiesi Global ...
Luxa Biotechnology reveals promising phase 1/2a trial results for RPESC-RPE therapy, showing safety and potential vision restoration in patients with dry AMD. Luxa is a clinical-stage biotechnology ...
EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research and fostering global networking among retina specialists. The 2025 European Society of Retina ...
The ultimate goal of redefining endpoints is enabling earlier diagnosis and treatment, said Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS ...
Conavi Medical has submitted its Novasight Hybrid IVUS/OCT intravascular imaging system to the US Food and Drug Administration (FDA) for 510(k) clearance for coronary applications. Conavi’s ...
Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and advancing retinal disease treatment. Kalaris Therapeutics announced the company ...
The European Commission (EC) has granted marketing authorization for EYLUXVI (ALT-L9), an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics. 1 EYLUXVI is ...
The window shop provision in the Alcon merger agreement enabled STAAR to accept a competing acquisition proposal and terminate the Alcon merger. STAAR Surgical announced the expiration of the 45-day ...
Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space. Modern imaging technologies, like advanced forms of optical coherence ...
Justis P. Ehlers, MD, FASRS, presented at the Retina Society meeting in Chicago, Illinois. His talk focused on the data from the HELIOS phase 1 trial, exploring a novel treatment for nonproliferative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback